Trails Edge Capital Partners LP Invests $1.66 Billion in ImageneBio, Inc. $IMA

Trails Edge Capital Partners LP acquired a new stake in shares of ImageneBio, Inc. (NASDAQ:IMA) in the 2nd quarter, HoldingsChannel.com reports. The firm acquired 282,004 shares of the company’s stock, valued at approximately $1,663,824,000.

A number of other institutional investors have also recently made changes to their positions in IMA. Barclays PLC increased its position in ImageneBio by 170.8% during the 4th quarter. Barclays PLC now owns 10,797 shares of the company’s stock valued at $74,000 after buying an additional 6,810 shares in the last quarter. Goldman Sachs Group Inc. acquired a new stake in ImageneBio in the fourth quarter worth about $76,000. Millennium Management LLC purchased a new stake in shares of ImageneBio during the fourth quarter worth about $79,000. T3 Companies LLC purchased a new stake in shares of ImageneBio during the fourth quarter worth about $91,000. Finally, Jane Street Group LLC purchased a new stake in shares of ImageneBio during the fourth quarter worth about $103,000. Institutional investors and hedge funds own 75.00% of the company’s stock.

ImageneBio Stock Performance

ImageneBio stock opened at $5.55 on Wednesday. The business’s 50-day simple moving average is $5.79 and its two-hundred day simple moving average is $5.83. The company has a market cap of $62.99 million, a PE ratio of -1.21 and a beta of 0.76. ImageneBio, Inc. has a fifty-two week low of $3.94 and a fifty-two week high of $14.00.

ImageneBio (NASDAQ:IMA) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.63) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.90) by $0.27. As a group, analysts predict that ImageneBio, Inc. will post -3.23 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. Wedbush reaffirmed an “underperform” rating on shares of ImageneBio in a research report on Monday, May 11th. Wall Street Zen downgraded shares of ImageneBio from a “sell” rating to a “strong sell” rating in a research report on Sunday, May 17th. Weiss Ratings restated a “sell (e+)” rating on shares of ImageneBio in a research note on Monday, June 29th. Finally, HC Wainwright initiated coverage on shares of ImageneBio in a report on Friday. They issued a “buy” rating and a $28.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $29.00.

Key Stories Impacting ImageneBio

Here are the key news stories impacting ImageneBio this week:

• Positive Sentiment: HC Wainwright initiated research coverage with a Buy rating and a $28 price target, substantially above the stock’s recent trading level. The firm expects ImageneBio to continue reporting losses but is maintaining a bullish view on the company’s longer-term prospects. ImageneBio Research Coverage Started at HC Wainwright
• Positive Sentiment: Reported short interest fell 87.2% to 49,297 shares as of August 14, representing only 0.4% of shares outstanding. The reduction lowers potential selling pressure and suggests fewer investors are betting against IMA, although the stock’s low trading volume limits the significance of the change.
• Neutral Sentiment: A separate report listed short interest at zero shares as of August 25, unchanged from zero previously. Because the report describes the change as “NaN” and conflicts with the August 14 figures, it appears to be a data-quality issue rather than a meaningful market development.
• Negative Sentiment: HC Wainwright’s detailed forecasts point to continued and potentially widening losses: EPS estimates are negative at $(3.57) for FY2026, $(5.48) for FY2027, and remain negative through FY2030. Persistent cash-burn and the absence of near-term profitability remain important risks, even with the firm’s Buy rating.

ImageneBio Profile

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025. ImageneBio, Inc is headquartered in San Diego, California.